1. Scope

This summary covers the use of intermittent fasting (IF) and related meal-timing protocols — time-restricted eating (TRE, e.g. 16:8, early-TRE), alternate-day fasting (ADF) and modified ADF, the 5:2 diet, whole-day fasting, and periodic fasting-mimicking diets (FMD) — as adjunctive longevity/preventive interventions, with autophagy induction as a proposed mechanism.[1][2]

Covered: biological rationale, human evidence for clinical and biomarker outcomes, patient selection, baseline work-up, practical protocols, monitoring, safety, contraindications, and clinic scenarios.

Not covered: management of established eating disorders, therapeutic fasting for active oncological treatment, paediatric use, religious fasting (e.g. Ramadan) as a primary indication, and pharmacological autophagy inducers (rapamycin, spermidine, metformin). Content is framed as adjunctive to conventional primary/secondary care, not a replacement for guideline-based therapy. Longevity-specific use (i.e. fasting to extend healthspan/lifespan or to slow biological ageing in metabolically healthy adults) is off-label / expert-consensus / largely research-stage; no regulator licenses fasting for anti-ageing indications.



2. Background and pathophysiology

– Metabolic switching is the core mechanism: after ~12 h of fasting, hepatic glycogen depletes and metabolism shifts to adipose-derived free fatty acids and ketones. This triggers an evolutionarily conserved adaptive stress response.[3][4]

– Key nutrient-sensing pathways: fasting activates AMPK and SIRT1/SIRT3 and inhibits mTOR, which de-represses ULK1 and TFEB, driving autophagy/mitophagy, mitochondrial biogenesis (PGC-1α), antioxidant defences, DNA repair, and reduced inflammation.[1][3]

– Ageing hallmarks targeted (mechanistic rationale): loss of proteostasis (autophagy), mitochondrial dysfunction, deregulated nutrient sensing, cellular senescence, and circadian misalignment.[5][6]

Most robust human mechanistic evidence:

– Autophagy: The only randomised human autophagic-flux data come from an exploratory analysis of an RCT in 121 adults with obesity — intermittent TRE showed higher LC3B-II flux in peripheral blood mononuclear cells versus standard care at 6 months (post-hoc, P = 0.04), but there was no significant within-group increase from baseline, and calorie restriction alone did not differ from control. This is hypothesis-generating only.[7]

– Biological age biomarkers: Periodic FMD (5 days/month × 3 cycles) was associated with a ~2.5-year reduction in a validated biological-age clock and lower hepatic fat in secondary/exploratory analyses of two small trials — surrogate endpoints, not clinical outcomes.[8]

Preclinical only (do not extrapolate to hard clinical benefit): the strongest longevity/lifespan-extension and senescent-cell-clearance data derive from rodent and lower-organism models; magnitude varies by sex, diet and genotype, and has not been demonstrated for human lifespan.[6][3][9]



3. Evidence base and grading

Available human evidence is dominated by short-to-medium-term RCTs (median ~3 months, small samples) synthesised in multiple umbrella reviews and network meta-analyses, plus prospective cohort data for mortality. Outcomes studied are overwhelmingly surrogate cardiometabolic endpoints (weight, adiposity, glycaemia, lipids, blood pressure); hard endpoints (mortality, MACE, incident disease) come only from observational cohorts, and no RCT has powered clinical events or lifespan.[2][10][11]

A GRADE summary of meal-timing RCTs illustrates the certainty landscape — most anthropometric/metabolic effects are low-to-moderate certainty, with a signal of lean-mass loss:

Table 2 Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Summary of Findings and Certainty of Evidence for Meal Timing for Anthropometric and Metabolic Measures

Outcome-by-outcome (GRADE-style):

– Body weight / adiposity — Moderate certainty. Network meta-analysis of 99 RCTs (n = 6582) found all IF strategies reduced weight vs ad-libitum; ADF was the only form modestly superior to continuous energy restriction (−1.29 kg, 95% CI −1.99 to −0.59), a difference of doubtful clinical significance, and benefits over ad-libitum attenuated in trials ≥24 weeks. Umbrella reviews concur that IF ≈ continuous energy restriction. Downgrades: short follow-up (indirectness/imprecision for durability). Conditional recommendation to offer as one option for weight/adiposity in overweight/obese adults.[13][14][10][2]

– Glycaemia (fasting glucose, HbA1c, insulin sensitivity) — Low-to-moderate certainty. TRE reduces fasting glucose (moderate) and fasting insulin, with small HbA1c effects (≈0.08–0.5%). Conditional recommendation as adjunct in dysglycaemia (with medication review, see safety).[15][16][12]

– Lipids — Low certainty. ADF may lower total cholesterol/triglycerides/non-HDL more than TRE; TRE effects on LDL are inconsistent. Conditional recommendation.[13][16]

– Blood pressure — Low certainty. Small reductions, sometimes independent of weight loss; one umbrella review found IF less effective than continuous energy restriction for systolic BP. Conditional recommendation.[16][17]

– Autophagy induction in humans — Very low certainty (single exploratory post-hoc analysis, no within-group change). Only in research.[7]

– Biological-age / “reduced ageing” biomarkers — Very low certainty (small exploratory FMD analyses; surrogate). Only in research — do not infer clinical anti-ageing benefit.[8]

– All-cause / cardiovascular mortality — Very low certainty and potentially cautionary. No RCT evidence. A large NHANES cohort (n = 33,052) found a U-shaped relationship: eating windows ≤8 h were associated with ≥30% higher all-cause and >50% higher cardiovascular mortality in older adults/men, with lowest risk at ~11–12 h. Recommend against using very short windows specifically to reduce mortality; Recommend against claiming mortality benefit.[11]

– Lean/muscle mass — Moderate certainty of a harm signal. Meta-analysis shows TRE reduces fat-free mass (−0.58 kg); the TREAT RCT found ~65% of weight lost was lean mass and a significant fall in appendicular lean mass. Effect is heterogeneous — younger adults without resistance training are most vulnerable; older cohorts variable. Strong recommendation to co-prescribe adequate protein and resistance training.[18][19][20]

Overall publication-bias/small-study concern is high (median RCT n ≈ 38); most associations rest on very-low/low-certainty evidence per JAMA Network Open and EClinicalMedicine umbrella reviews.[10][2]



4. Patient selection and indications

Who may benefit (adjunctive, with informed consent):

– Middle-aged adults with overweight/obesity and cardiometabolic risk (raised waist circumference, prediabetes, dyslipidaemia, hypertension, MASLD) — the population where evidence is strongest.[13][14][10][2]

– Adults preferring meal-timing structure over daily calorie counting (adherence advantage).[15]

– FMD-style periodic cycles have been studied predominantly in adults at cardiometabolic risk, where benefit was greatest.[21]

Inclusion (pragmatic): age ~18–70, BMI ≥25 kg/m² or ≥1 cardiometabolic risk factor, able to self-monitor and maintain protein/hydration.

Exclusion / high-risk groups (avoid or specialist input only):

– Type 1 diabetes (avoid; high hypoglycaemia risk); type 2 diabetes on insulin/sulfonylureas/meglitinides (specialist + dose adjustment).[22]

– History of eating disorder or disordered eating; underweight/BMI <18.5.[23]

– Frailty, sarcopenia, or high sarcopenia risk (lean-mass loss).[19][20]

– Pregnancy/breastfeeding; children/adolescents; age >75 or significant frailty.[23][24]

– Active peptic ulcer disease / prior upper-GI bleeding; gout (avoid dehydration-related flares).[22]

– Advanced renal or hepatic impairment; anyone on medication requiring food-timed dosing.

Regulatory/ethical status: IF/TRE/FMD are dietary behaviours, not regulated medicinal interventions; use for longevity/anti-ageing is off-label by concept and expert-consensus/research-stage. Frame explicitly as adjunctive lifestyle care with documented informed consent; autophagy- and biological-age-based justifications should be presented as research-stage/mechanistic only.



5. Assessment and baseline work-up

History & examination: cardiometabolic and weight history; medications (especially glucose-lowering, antihypertensives, anticoagulants, drugs requiring food); eating-disorder screen (e.g. SCOFF); frailty/sarcopenia screen in older adults; alcohol; hydration and GI history; dietary/protein pattern; physical activity (particularly resistance training).

Baseline investigations (tailor to risk):

– Bloods: HbA1c/fasting glucose, fasting lipids, U&E and eGFR, LFTs, FBC, urate; consider hs-CRP.

– Anthropometry: weight, waist circumference, BMI; DXA or bioimpedance for baseline lean/fat mass where sarcopenia risk exists.[19][20]

– BP; grip strength / gait speed or SPPB in older adults.

– MASLD assessment where indicated.

– Ageing biomarkers (biological-age clocks, autophagy flux) are research tools only — use within registries/trials, not for clinical decisions.[7][8]

Risk stratification: Low risk — metabolically healthy middle-aged adult, no exclusions. Moderate — controlled T2D on non-hypoglycaemic agents, mild MASLD, older but robust. High — insulin/sulfonylurea use, frailty/sarcopenia, prior eating disorder, GI ulcer history → specialist/MDT input or avoid.

Baseline documentation: weight/waist/BMI, body composition if measured, BP, relevant bloods, medication list, chosen protocol, consent (including off-label/research-stage framing), and a defined review date.



6. Dosing regimens and practical implementation

Non-pharmacological; “dose” = fasting duration, frequency, timing, and duration of programme.

Regimens with the most robust human data (cardiometabolic surrogates):

– TRE 16:8 (8–10 h eating window): the best-studied and most tolerated daily protocol; early-TRE (eating window earlier in the day) aligns with circadian biology and may confer additional glucose/BP benefit.[15][25][26]

– 5:2 diet: ~500–600 kcal on 2 non-consecutive days weekly; normal eating for 5 days.[2]

– Modified ADF: ~25% of energy needs (~500 kcal) on fasting days; strongest single signal for weight/metabolic benefit in umbrella reviews.[27][10]

Practical implementation:

– Start conservatively (e.g. 12:12 → 14:10 → 16:8 over 2–4 weeks) to improve tolerability.

– Prioritise protein (aim ~1.0–1.6 g/kg/day) distributed within the eating window, plus resistance training ≥2×/week to protect lean mass — a strong recommendation given the muscle-loss signal.[19][20]

– Maintain hydration and non-caloric fluids during fasts; sustain diet quality (Mediterranean-style pattern).[4]

– Avoid windows ≤8 h as a default, especially in older adults, given the cohort mortality signal and lean-mass risk.[20][11]

Regimens requiring caution (extrapolated / early-phase data):

– Periodic FMD (5 days/month × 3+ cycles): benefits on biological-age surrogates from small exploratory trials — reasonable to consider in at-risk adults but positioned as emerging/research-supported, not established.[21][8]

– Prolonged multi-day water fasting and OMAD: limited controlled data, higher adverse-event profile (postural hypotension, gout, arrhythmia, muscle wasting) — not recommended outside specialist supervision or research.[22]



7. Monitoring, safety and follow-up

Monitoring plan:

– Clinical: weight, waist, BP, symptoms of hypoglycaemia/postural hypotension, hydration, GI symptoms, energy/sleep, disordered-eating behaviours.

– Laboratory: HbA1c/glucose, lipids, U&E, urate, LFTs as indicated.

– Functional/body composition: periodic DXA/bioimpedance and grip strength/gait speed in those at sarcopenia risk.[19][20]

– Ageing biomarkers: only within research/registry frameworks.[7][8]

Timepoints: review at 2–4 weeks (tolerability, hypoglycaemia, medication adjustment), 3 months (metabolic response, body composition trend), then 6–12 monthly long-term with reinforcement of protein/resistance training and reassessment of ongoing benefit.

Adverse effects:

– Common: hunger, headache, fatigue, dizziness, irritability, insomnia, dyspepsia, dehydration.[23]

– Notable/expected with certain regimens: loss of lean/appendicular muscle mass (moderate-certainty signal).[18][19]

– Serious but less common (mainly prolonged/aggressive fasting): hypoglycaemia (severe in insulin/sulfonylurea users), postural hypotension/syncope, cardiac arrhythmia, gout flare, peptic ulcer worsening/upper-GI bleeding, precipitation/relapse of eating disorder.[22]

Actions for abnormal findings: hypoglycaemia → reduce/hold offending agent and reduce fasting intensity; falling lean mass or grip strength → increase protein, intensify resistance training, lengthen eating window/stop; disordered-eating features → stop and refer; recurrent syncope/arrhythmia → stop and investigate.

Interactions:

– Insulin, sulfonylureas, meglitinides: high hypoglycaemia risk — reduce dose ~50% on fasting days (may need more), with glucose monitoring and diabetes-team input.[22]

– Antihypertensives/diuretics: monitor for hypotension/dehydration.

– Warfarin and vitamin-K intake changes, lithium (fluid/sodium shifts), and food-dependent drugs: review timing.

– Concurrent GLP-1 agonists or other calorie-reducing interventions may compound lean-mass loss and nausea.

Special populations: avoid in pregnancy/breastfeeding; caution and specialist input in renal/hepatic impairment; in frailty and extremes of age, prioritise protein/resistance training and favour modest windows (≥10–12 h) or avoid — older adults show the strongest short-window mortality signal.[24][11]



8. Contraindications and cautions

Absolute contraindications:

– Type 1 diabetes (routine use).[22]

– Pregnancy and breastfeeding.

– Active or past eating disorder / significant disordered eating.[23]

– Underweight (BMI <18.5) or clinically significant malnutrition.

– Children and adolescents.

Relative (specialist advice / caution):

– Type 2 diabetes on insulin or secretagogues.[22]

– Frailty, sarcopenia, advanced age.[20][11]

– Peptic ulcer disease / prior GI bleed; gout.[22]

– Renal or hepatic impairment; drugs requiring food-timed dosing.

Harm likely > benefit with current evidence: using very short (≤8 h) windows or prolonged/repeated multi-day fasts specifically for anti-ageing/longevity in metabolically healthy or older adults — mortality and muscle-loss signals argue against this.[20][11]



9. Practical management scenarios

Scenario A — Middle-aged adult with multiple cardiometabolic risk factors (overweight, prediabetes, hypertension).

Recommendation: Offer as one adjunctive option (conditional recommendation).[13][14][10]

– Assessment: cardiometabolic bloods, waist/BMI/BP, medication review, eating-disorder screen.

– Shared decision-making: explain IF ≈ continuous energy restriction for weight/metabolic outcomes; benefits are surrogate, off-label for longevity; document consent.[13][10]

– Initiation: early-TRE 16:8 (or 5:2), stepped up over 2–4 weeks; protein ~1.0–1.6 g/kg/day; resistance training ≥2×/week; Mediterranean-style diet quality.[25][4]

– Monitoring: 2–4 week tolerability check, 3-month metabolic review.

– Escalate/stop: hypoglycaemia, disordered eating, or no benefit by 3–6 months.

Scenario B — Older, frail patient with multimorbidity.

Recommendation: generally avoid / restrict to specialist-supervised use.[20][11]

– Assessment: frailty/sarcopenia and nutritional status; grip strength/gait speed; DXA if feasible.

– Rationale: short windows associated with higher all-cause and CV mortality in older adults, plus lean-mass loss risk.[20][11]

– If pursued: only a modest window (≥10–12 h overnight fast), high protein, supervised resistance training, close monitoring of weight/muscle.

– Stop: any weight/muscle loss, functional decline, or hypotension.

Scenario C — Patient under specialist care (e.g. type 2 diabetes on insulin, or MASLD) wanting IF as an adjunct.

Recommendation: Consider only with the responsible specialist and structured monitoring (conditional).[22]

– Assessment: current regimen, hypoglycaemia risk, glucose monitoring capability.

– Shared decision-making + consent: coordinate with diabetes/hepatology team.

– Initiation: reduce insulin/sulfonylurea ~50% on fasting days; provide CGM/SMBG; dietitian and diabetes-educator involvement.[22]

– Monitoring: frequent glucose review early; LFTs/imaging for MASLD as per specialist.

– Escalate/stop: recurrent hypoglycaemia, ketosis concerns, or destabilisation.



10. Research gaps and future directions

– No RCTs powered for hard clinical endpoints (mortality, MACE, incident disease, healthspan/lifespan); current evidence is short-term surrogate data.[2][10]

– Human autophagy induction is essentially unproven clinically — the single randomised flux analysis was exploratory with no within-group change; validated, accessible autophagy biomarkers are needed.[7]

– Biological-age reductions are surrogate only — the link between fasting-induced clock changes and clinical outcomes is unestablished.[8]

– Optimal protocol undefined: window length/timing (early vs late TRE), frequency, and FMD cycling need head-to-head trials; the U-shaped mortality signal for ≤8 h windows requires prospective testing.[13][11][26]

– Muscle preservation: trials defining protein targets, timing, and resistance-training co-prescription to prevent lean-mass loss, particularly in older adults.[18][20]

– Special populations: older/frail adults, T2D on hypoglycaemic agents, and women (sex-specific effects) are under-studied.

Until adequately powered trials exist, longevity-specific and autophagy-driven fasting should ideally be delivered within well-designed clinical trials or prospective registries; outside these, IF is best justified for cardiometabolic risk reduction as adjunctive care, not as a validated anti-ageing therapy.

References

1. Intermittent Fasting: Impact, Mechanisms and Cautions Across Medical and Lifestyle Domains. Gautam KA, Lal P, Malik T, et al. European Journal of Clinical Nutrition. 2026;:10.1038/s41430-026-01768-5. doi:10.1038/s41430-026-01768-5.
2. Intermittent fasting for weight management and metabolic health: An updated comprehensive umbrella review of health outcomes. Hua Z, Yang S, Li J, et al. Diabetes, Obesity & Metabolism. 2025;27(2):920-932. doi:10.1111/dom.16092.
3. Effects of Intermittent Fasting on Health, Aging, and Disease. de Cabo R, Mattson MP. The New England Journal of Medicine. 2019;381(26):2541-2551. doi:10.1056/NEJMra1905136.
4. A Pesco-Mediterranean Diet With Intermittent Fasting: JACC Review Topic of the Week. O’Keefe JH, Torres-Acosta N, O’Keefe EL, et al. Journal of the American College of Cardiology. 2020;76(12):1484-1493. doi:10.1016/j.jacc.2020.07.049.
5. Effects of Chrononutrition on Aging and Lifespan. Wang Y, Zhang S, Xiang P, et al. Food Research International (Ottawa, Ont.). 2026;236:119237. doi:10.1016/j.foodres.2026.119237.
6. Interplay Between Autophagy, Cellular Senescence, and Brain Aging: Neuroprotective Implications of Intermittent Fasting. Singh I, Bhat S, Tamatta R, Singh AK. Cellular and Molecular Neurobiology. 2026;46(1):75. doi:10.1007/s10571-026-01709-7.
7. Intermittent Time-Restricted Eating May Increase Autophagic Flux in Humans: An Exploratory Analysis. Bensalem J, Teong XT, Hattersley KJ, et al. The Journal of Physiology. 2025;603(10):3019-3032. doi:10.1113/JP287938.
8. Fasting-Mimicking Diet Causes Hepatic and Blood Markers Changes Indicating Reduced Biological Age and Disease Risk. Brandhorst S, Levine ME, Wei M, et al. Nature Communications. 2024;15(1):1309. doi:10.1038/s41467-024-45260-9.
9. Intermittent Fasting and Longevity: From Animal Models to Implication for Humans. Strilbytska O, Klishch S, Storey KB, Koliada A, Lushchak O. Ageing Research Reviews. 2024;96:102274. doi:10.1016/j.arr.2024.102274.
10. Intermittent Fasting and Obesity-Related Health Outcomes: An Umbrella Review of Meta-analyses of Randomized Clinical Trials. Patikorn C, Roubal K, Veettil SK, et al. JAMA Network Open. 2021;4(12):e2139558. doi:10.1001/jamanetworkopen.2021.39558.
11. Association of Eating Window With Mortality Among US Adults: Insights From a Nationally Representative Study. Mao Z, Grant H, Kritchevsky SB, Newman AB, Farsijani S. Aging Cell. 2025;:e70230. doi:10.1111/acel.70230.
12. Meal Timing and Anthropometric and Metabolic Outcomes: A Systematic Review and Meta-Analysis. Liu HY, Eso AA, Cook N, O’Neill HM, Albarqouni L. JAMA Network Open. 2024;7(11):e2442163. doi:10.1001/jamanetworkopen.2024.42163.
13. Intermittent Fasting Strategies and Their Effects on Body Weight and Other Cardiometabolic Risk Factors: Systematic Review and Network Meta-Analysis of Randomised Clinical Trials. Semnani-Azad Z, Khan TA, Chiavaroli L, et al. BMJ (Clinical Research Ed.). 2025;389:e082007. doi:10.1136/bmj-2024-082007.
14. Longer-Term Effects of Intermittent Fasting on Body Composition and Cardiometabolic Health in Adults With Overweight and Obesity: A Systematic Review and Meta-Analysis. Khalafi M, Maleki AH, Ehsanifar M, Symonds ME, Rosenkranz SK. Obesity Reviews : An Official Journal of the International Association for the Study of Obesity. 2025;26(2):e13855. doi:10.1111/obr.13855.
15. Time-Restricted Eating as a Potential Strategy for Healthy Lifespan: An Evaluation of Current Evidence. Wu H, Shi Y, Wang Z, et al. Frontiers in Medicine. 2025;12:1701888. doi:10.3389/fmed.2025.1701888.
16. Intermittent Fasting and Health Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses of Randomised Controlled Trials. Sun ML, Yao W, Wang XY, et al. EClinicalMedicine. 2024;70:102519. doi:10.1016/j.eclinm.2024.102519.
17. Current Research: Effect of Time Restricted Eating on Weight and Cardiometabolic Health. Gabel K, Varady KA. The Journal of Physiology. 2022;600(6):1313-1326. doi:10.1113/JP280542.
18. Efficiency of Time-Restricted Eating and Energy Restriction on Anthropometrics and Body Composition in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Sun Y, Liu Y, Ye W, et al. The International Journal of Behavioral Nutrition and Physical Activity. 2025;22(1):121. doi:10.1186/s12966-025-01812-w.
19. Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity. Lowe DA, Wu N, Rohdin-Bibby L, et al. JAMA Internal Medicine. 2020;180(11):1491-1499. doi:10.1001/jamainternmed.2020.4153.
20. Time-Restricted Feeding/Eating and Muscle Aging: Research Progress From Molecular Mechanisms to Personalized Intervention Strategies. Liu J, Huang K, Qian J, Zhai Q. Nutrition Reviews. 2026;:nuag095. doi:10.1093/nutrit/nuag095.
21. Fasting-Mimicking Diet and Markers/Risk Factors for Aging, Diabetes, Cancer, and Cardiovascular Disease. Wei M, Brandhorst S, Shelehchi M, et al. Science Translational Medicine. 2017;9(377):eaai8700. doi:10.1126/scitranslmed.aai8700.
22. Intermittent fasting and ‘metabolic switch’: Effects on metabolic syndrome, prediabetes and type 2 diabetes. Rajpal A, Ismail-Beigi F. Diabetes, Obesity & Metabolism. 2020;22(9):1496-1510. doi:10.1111/dom.14080.
23. Intermittent Fasting for Adults With Overweight or Obesity. Garegnani LI, Oltra G, Ivaldi D, et al. The Cochrane Database of Systematic Reviews. 2026;2:CD015610. doi:10.1002/14651858.CD015610.pub2.
24. Impact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease: JACC Scientific Statement. Forman DE, Kuchel GA, Newman JC, et al. Journal of the American College of Cardiology. 2023;82(7):631-647. doi:10.1016/j.jacc.2023.05.038.
25. Effectiveness of Early Time-Restricted Eating for Weight Loss, Fat Loss, and Cardiometabolic Health in Adults With Obesity. Jamshed H, Steger FL, Bryan DR, et al. JAMA Internal Medicine. 2022;182(9):953-962. doi:10.1001/jamainternmed.2022.3050.
26. Role of Circadian Health in Cardiometabolic Health and Disease Risk: A Scientific Statement From the American Heart Association. Knutson KL, Dixon DD, Grandner MA, et al. Circulation. 2025;152(21):e408-e419. doi:10.1161/CIR.0000000000001388.
27. Effects of Different Types of Intermittent Fasting on Metabolic Outcomes: An Umbrella Review and Network Meta-Analysis. Chen YE, Tsai HL, Tu YK, Chen LW. BMC Medicine. 2024;22(1):529. doi:10.1186/s12916-024-03716-1.